In Interim Results ts 2016 - September 2016 Midatech Pharma plc - PowerPoint PPT Presentation

Aug 18, 2022 •281 likes •586 views

In Interim Results ts 2016 - September 2016 Midatech Pharma plc Disclaimer THIS PRESENTATION MAY NOT BE COPIED OR REPRODUCED IN ANY FORM, FURTHER DISTRIBUTED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON, OR PUBLISHED, IN WHOLE OR

In Interim Results ts 2016 - September 2016 Midatech Pharma plc

Download Presentation

Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

INTERIM RESULTS PRESENTATION 6 MONTHS ENDED 30 JUNE 2016 September 2016 INTERIM RESULTS

INTERIM RESULTS PRESENTATION 6 MONTHS ENDED 30 JUNE 2016 September 2016 INTERIM RESULTS PRESENTATION Contents 1 First Half review 2 Full Year outlook 3 Financial Appendices 2 1. 2016 FIRST HALF REVIEW 2016 FIRST HALF REVIEW We go to

714 views • 38 slides

Interim results for the period November 2016 ending 30 September 2016 Russell Down, Chief

Interim results for the period November 2016 ending 30 September 2016 Russell Down, Chief Executive Results significantly improved; recovery well established Financial highlights Pre-disposal revenue increased by 5.2% to 171.4m (2015:

270 views • 24 slides

INTERIM RESULTS Half year ended 30 September 2016 29 th November 2016 Overview A good set of

INTERIM RESULTS Half year ended 30 September 2016 29 th November 2016 Overview A good set of results in difficult conditions Further EPS growth, up >70% last 3 years Focused on: Building new project business to drive future

605 views • 29 slides

Applegreen plc H1 2016 Interim Results Presentation 6 th September 2016 Private and Confidential

Applegreen plc H1 2016 Interim Results Presentation 6 th September 2016 Private and Confidential Disclaimer This document, which is personal to the recipient and has been issued by Applegreen plc (the Company), comprises written

510 views • 29 slides

Venture Life Group plc Interim results presentation Six months to 30 June 2016 September 2016

Venture Life Group plc Interim results presentation Six months to 30 June 2016 September 2016 Agenda H1 2016 highlights Global progress Operational leverage Update on Periproducts acquisition Commercial update Financial

681 views • 28 slides

Interim results for the six months ended 30 June 2016 16 September 2016 Denise Scots-Knight

Interim results for the six months ended 30 June 2016 16 September 2016 Denise Scots-Knight CEO Richard Bungay CFO & COO Disclaimer This document has been prepared in good faith and with reasonable care, however the information,

419 views • 27 slides

Interim Results Presentation For the period ended 30 September 2016 CONTENTS Financial

Interim Results Presentation For the period ended 30 September 2016 CONTENTS Financial overview South African operations West Coast Resources operations Angolan operations Conclusion Trans Hex Group Interim Results

246 views • 20 slides

Investor Presentation FY17 Interim Results - 30 September 2016 December 2016 2 Introduction

Investor Presentation FY17 Interim Results - 30 September 2016 December 2016 2 Introduction Neil Thompson mpson Chief Financial Officer, MAG Ken OToole Divisional Chief Executive Officer, Manchester Airport 3 Contents FY17 H H1 H

626 views • 30 slides

2016 H1 Interim Results and Project Update September 2016 Disclaimer Certain statements within

2016 H1 Interim Results and Project Update September 2016 Disclaimer Certain statements within this presentation constitute forward looking statements. Such forward looking statements involve risks and other factors which may cause the actual

501 views • 27 slides

Interim Results Presentation Wednesday 7 September 2016 Agenda Key highlights and group

Independent, global provider of corporate, fund and private client administration services Interim Results Presentation Wednesday 7 September 2016 Agenda Key highlights and group overview Dean Godwin Financial review Spencer

229 views • 21 slides

Orient Overseas (International) Ltd Interim Results Presentation 2016 August 8th 2016 1 Key

Orient Overseas (International) Ltd Interim Results Presentation 2016 August 8th 2016 1 Key Financial and Operational Highlights Revenue (2016 1H): US$ 2.6 billion Loss after tax (2016 1H): (US$ 57 million) Debt (2016 Jun 30): US$

620 views • 51 slides

2016 Interim Results August 2016 BBA Aviation transformed in H1 2016 Operating profit 1

2016 Interim Results August 2016 BBA Aviation transformed in H1 2016 Operating profit 1 Revenue by key markets The enlarged Signature Military Aftermarket Flight Landmark Aviation as anticipated 5% Services Support Commercial 7%

610 views • 26 slides

Interim Results - September 2016 Performance Overview Statutory Normalised* Revenue R9.17bn

Interim Results - September 2016 Performance Overview Statutory Normalised* Revenue R9.17bn 1.5% Operating profit R1.25bn (13.4%) R1.29bn (4.2%) EBITDA R1.37bn (11.5%) R1.41bn (2.9%) Diluted HEPS 351.2c (13.7%) 360.4c (4.9%)

506 views • 37 slides

Interim Results for the six months ended 29 February 2016 12 April 2016 1 Nick Beighton CEO

Interim Results for the six months ended 29 February 2016 12 April 2016 1 Nick Beighton CEO 2 HY 2016 Highlights Total sales +21%, PBT 21.2m Continued acceleration Strong peak trading performance Accelerated

488 views • 35 slides

2016 Interim Results 25 August 2016 Disclaimer This presentation has been issued by PV Crystalox

PV Crystalox Solar plc 2016 Interim Results 25 August 2016 Disclaimer This presentation has been issued by PV Crystalox Solar plc (the Company ) and comprises of written materials/slides concerning the Companys Interim Results for

439 views • 15 slides

Interim results for the 6 months to 30 June 2015 SEPTEMBER 2015 Interim Results September 2015

Interim Results September 2015 Interim results for the 6 months to 30 June 2015 SEPTEMBER 2015 Interim Results September 2015 CELLO INTRODUCTION We supply marketing advisory services primarily in the pharmaceutical sector Global

419 views • 27 slides

Activating the Redeye pre-ASCO seminar immune system to Dr. Erik D Wiklund - CBO Company

Activating the Redeye pre-ASCO seminar immune system to Dr. Erik D Wiklund - CBO Company presentation fight cancer 28 May 2019 August 2018 IMPORTANT NOTICE AND DISCLAIMER This report contains certain forward-looking statements based on

877 views • 14 slides

Small Cell Carcinoma of the Ovary: Report of a Case with Unusual and Aggressive Presentation

Case Report Middle East Journal of Cancer; July 2017; 8(3): 161-165 Small Cell Carcinoma of the Ovary: Report of a Case with Unusual and Aggressive Presentation Fatemeh Sadat Najib* , ***, Mojdeh Momtahan*, Maral Mokhtari**, Shaghayegh Moradi

607 views • 5 slides

computerized tomographic scan confirmed bilateral with dermatomyositis, there was a high incidence

RESEARCH LETTER D ERMATOMYOSITIS AS THE I NITIAL P RESENTATION OF O VARIAN C ANCER Lai-Wan Chao, Lin-Hung Wei 1 * Departments of Obstetrics and Gynecology, and 1 Oncology, National Taiwan University Hospital and National Taiwan University

174 views • 3 slides

ASCOs Quality Training Program Project Title: Improving oral chemotherapy fulfillment processes

ASCOs Quality Training Program Project Title: Improving oral chemotherapy fulfillment processes and implementation of a pharmacist- managed oral chemotherapy follow-up program Presenters Name: Sonja Jacobsen, PharmD Firas Shadad, MD

506 views • 22 slides

neoplasia and intraductal papillary mucinous neoplasm Xianzhong Ding, Brandon Trac, and Xiuzhen

Expression of GRP78 protein is increased in pancreatic ductal adenocarcinoma, pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasm Xianzhong Ding, Brandon Trac, and Xiuzhen Duan Department of Pathology Loyola

133 views • 12 slides

CORPORATE PRESENTATION A ROYALTY AGGREGATION COMPANY JANUARY 2020 NASDAQ: XOMA 1

CORPORATE PRESENTATION A ROYALTY AGGREGATION COMPANY JANUARY 2020 NASDAQ: XOMA 1 DISCLAIMERS Certain statements in this presentation are forward-looking Potential risks to XOMA meeting these expectations are statements within the meaning

825 views • 28 slides

September 2019 1 Safe Harbor Statement This presentation contains forward-looking statements

INODIFTAGENE Gene Therapy for Bladder Cancer September 2019 1 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of U.S. federal securities laws and Israeli securities laws that involve risks and

297 views • 16 slides

Genomics in science and clinical care Frdrique Nowak Institut National du Cancer October

Genomics in science and clinical care Frdrique Nowak Institut National du Cancer October 8, 2012 I nstitut national du cancer (I NCa) The French National Cancer Institute is a health and science agency dedicated to oncology.

204 views • 19 slides